PLSE
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive advantages of the Company\'s proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model.
Pulse Biosciences, Inc. (PLSE) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Value (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | F (0.0) | B+ (3.8) | C- (2.1) | B (3.5) | C+ (2.6) | C (2.4) |
| 2026-11-07 | F (0.0) | B+ (3.8) | C (2.3) | A- (3.9) | C+ (2.7) | C+ (2.5) |
| 2026-10-31 | F (0.0) | B (3.2) | D+ (1.6) | A- (4.1) | C+ (2.7) | C (2.3) |
| 2026-10-24 | F (0.0) | B (3.2) | D+ (1.6) | A+ (4.5) | C+ (2.6) | C (2.4) |
| 2026-10-17 | F (0.0) | B (3.2) | D+ (1.6) | A+ (4.6) | C+ (2.6) | C (2.4) |